Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why These 5 Stocks Are Immersed in a Sea of Red Today

With all three indices in the green today, shares of Cardiovascular Systems Inc (NASDAQ:CSII), Agile Therapeutics Inc (NASDAQ:AGRX), Spectranetics Corp (NASDAQ:SPNC), LDR Holding Corp (NASDAQ:LDRH), and Tutor Perini Corp (NYSE:TPC) are not partaking in the fun, as all five stocks are well in the red. Let’s find out why investors are selling these five stocks today as well as what relevant hedge funds have to say about them.

While there are many metrics that investors can assess in the investment process, hedge fund sentiment is something that is often overlooked. However, hedge funds and other institutional investors allocate significant resources while making their bets and their long-term focus makes them the perfect investors to emulate. This is supported by our research, which determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor beat the S&P 500 by around 95 basis points per month (see more details here).

First on the list is Cardiovascular Systems Inc (NASDAQ:CSII), whose stock has plummeted by 30% after the company reported a loss of $0.47 per share on revenue of $41.4 million for the second quarter of fiscal year 2016, down by 4% from the second quarter of the prior fiscal year.  Although Cardiovascular Systems beat earnings estimates by $0.03 per share, the company missed revenue expectations by $3.43 million. Guidance was a little disappointing, with management expecting  a loss per share ranging from $0.42 to $0.45 on revenue of between $40.5 million and $42 million for the third quarter of fiscal year 2016.

Hedge funds were pessimistic about the stock in the third quarter. Our data shows that 14 funds that we track owned the company’s shares at the end of the third quarter, down by six from the end of June. Mitchell Blutt’s Consonance Capital Management reported holding a $36.86 million position in the stock as of the end of September, comprising 5.2% of its 13F portfolio.

Follow Cardiovascular Systems Inc (NASDAQ:CSII)
Trade (NASDAQ:CSII) Now!

Moving on, Agile Therapeutics Inc (NASDAQ:AGRX) shares have lost 10% today after the company announced the pricing of its public offering of 5.51 million shares at $6.35 per share. Moreover, the offering allows underwriters, via an overallotment option, to issue an additional 826,771 shares. The company, which specializes in contraceptive products, plans to use the funds for general purposes as it continues to develop its product candidates.

Out of the 730 funds that we track, nine funds held shares of Agile Therapeutics Inc (NASDAQ:AGRX) on September 30, amassing 27.9% of the float, down slightly from 10 funds on June 30. Dennis Purcell‘s Aisling Capital was the largest shareholder of Agile Therapeutics in our system, owning 2.98 million shares valued at $20.11 million at the end of September.

Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Trade (NASDAQ:AGRX) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.